跳至主要内容
临床试验/JPRN-jRCTs031180206
JPRN-jRCTs031180206已完成4 期

The exploratory study for the efficacy and the safety of Rikkunshito on symptoms of indigestion in the patients with Functional Heartburn

Iwakiri Katsuhiko0 个研究点目标入组 10 人开始时间: 2019年3月7日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
10

研究概览

简要总结

Publish in the paper

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • (1) Patients diagnosed with FH according to the Rome IV criteria
  • (2)Patients with indigestion(ARD>=1)
  • (3) FSSG is>=8
  • (4)Patients who are resistant to even more than 2 weeks administration of P-CAB.
  • (5) Type of visit: Outpatient
  • (6) Patients for whom oral administration was possible
  • (7) Patients who provided written informed consent regarding study participation

排除标准

  • (1)Patients diagnosed with Eosinophilic esophagitis(EoE)
  • (2)Patients diagnosed with Esophageal Motility disorders by High-Resolution manometry.
  • (3)Patients who had 50% or more of Symptom Index by 24-hour Esophageal Impedance and PH monitoring.
  • (4)Patients diagnosed with Reflux esophagitis (RE) (Los Angeles classification,>=Grade A)by upper endoscopy.
  • (5)History of upper GI resection
  • (6)Confirmed presence of ulcer (excluding scars) or malignant tumor in the upper GI.
  • (7)Suspected organic hepatic/biliary/pancreatic disorders such as gallstone, hepatitis, and pancreatitis
  • (8)History of allergic reactions to Kampo medicines.
  • (9)Patients who were administered Kampo medicine 4 weeks before entry.
  • (10)Receiving or scheduled to receive an agent that is being developed.
  • (11)Presence of serious complications (liver, kidney, heart, or blood disease or metabolic disease).
  • (12)Pregnant or lactating women or those who are planning to conceive during the study period.
  • (13)Considered ineligible to participate by principal investigator or sub-investigator

研究者

发起方
Iwakiri Katsuhiko

相似试验